Microbiome
We guide universities, research institutions, academic medical centers, and business leaders to protect their microbiome patent and related innovations.
/Overview
Our patent attorneys guide inventors and emerging-growth companies in the development and commercialization of their microbiome innovation and related portfolios to maximize the value of IP assets.
As this therapeutic arena grows and more treatments gain authorization, our microbiome patent prosecution, litigation, and transactional experience will increasingly serve as a competitive advantage for our clients in this ecosystem.
/Representative experience
- Postbiotics+, Inc.: Representing the microbiome company using ecosystem science to harness the power of the microbiome to improve health, in patent prosecution and strategic analyses.
- Infinant Health, Inc.: Advised the infant health company dedicated to discovering and implementing microbiome-based solutions that recognize how infant diet and microbiome interact to improve short- and long-term health of infants worldwide, in general intellectual property matters.
- Cedars-Sinai Medical Center: Represented the academic medical center in microbiome patent prosecution, clinical research transactions, license agreements, and Paragraph IV litigation relating to the use of rifaximin (marketed as XIFAXAN by Salix Pharmaceuticals) for the treatment of irritable bowel syndrome and associated diagnostic tools, leveraging a novel microbiome paradigm for the diagnosis and treatment of disease.
- ResBiotic, Inc.: Represented the biotechnology company focused on microbiome innovation, based on nutritional and therapeutic products for respiratory health on patent preparation, prosecution, and related IP counseling matters surrounding a microbial drug delivery platform targeting the gut-lung axis and inhaled microbial therapeutics.
/Recognition
- A Watershed Moment for Microbiome-Based Therapy
Boston Intellectual Property partner Mark FitzGerald and patent specialist Alissa Young, co-leaders of the IPPG Microbiome team, contributed this article discussing recent FDA approvals of microbiome-based therapies and an anticipated increase in patent enforcement litigation that could follow.